10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

OCUL (Ocular Therapeutix Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ocular Therapeutix Inc together

I guess you are interested in Ocular Therapeutix Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Ocular Therapeutix Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Ocular Therapeutix Inc’s Price Targets

I'm going to help you getting a better view of Ocular Therapeutix Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.

1. Quick Overview

1.1. Quick analysis of Ocular Therapeutix Inc (30 sec.)










1.2. What can you expect buying and holding a share of Ocular Therapeutix Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$1.57
Expected worth in 1 year
$0.58
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.99
Return On Investment
-10.9%

For what price can you sell your share?

Current Price per Share
$9.10
Expected price per share
$6.86 - $11.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ocular Therapeutix Inc (5 min.)




Live pricePrice per Share (EOD)
$9.10
Intrinsic Value Per Share
$-11.87 - $-7.57
Total Value Per Share
$-10.30 - $-6.00

2.2. Growth of Ocular Therapeutix Inc (5 min.)




Is Ocular Therapeutix Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$265.9m$127.5m$200.2m61.1%

How much money is Ocular Therapeutix Inc making?

Current yearPrevious yearGrowGrow %
Making money-$48.1m-$28.8m-$19.3m-40.2%
Net Profit Margin-347.1%-194.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Ocular Therapeutix Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#211 / 884

Most Revenue
#254 / 884

Most Profit
#784 / 884

Most Efficient
#628 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ocular Therapeutix Inc?

Welcome investor! Ocular Therapeutix Inc's management wants to use your money to grow the business. In return you get a share of Ocular Therapeutix Inc.

First you should know what it really means to hold a share of Ocular Therapeutix Inc. And how you can make/lose money.

Speculation

The Price per Share of Ocular Therapeutix Inc is $9.1. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ocular Therapeutix Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ocular Therapeutix Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.57. Based on the TTM, the Book Value Change Per Share is $-0.25 per quarter. Based on the YOY, the Book Value Change Per Share is $0.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ocular Therapeutix Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-4.2%-0.29-3.2%-0.18-2.0%-0.20-2.2%-0.17-1.9%-0.13-1.5%
Usd Book Value Change Per Share-0.31-3.4%-0.25-2.7%0.636.9%0.091.0%0.080.9%0.030.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.31-3.4%-0.25-2.7%0.636.9%0.091.0%0.080.9%0.030.3%
Usd Price Per Share7.33-7.85-5.47-5.79-7.93-7.66-
Price to Earnings Ratio-4.85--7.17--65.99--26.84--8.07--15.29-
Price-to-Total Gains Ratio-23.88--34.06--1.51--24.65-27.23--151.38-
Price to Book Ratio4.67-4.09-85.33-40.07-28.94-20.56-
Price-to-Total Gains Ratio-23.88--34.06--1.51--24.65-27.23--151.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.1
Number of shares109
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.250.08
Usd Total Gains Per Share-0.250.08
Gains per Quarter (109 shares)-27.018.98
Gains per Year (109 shares)-108.0435.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-108-11803626
20-216-22607162
30-324-334110798
40-432-4421143134
50-540-5501178170
60-648-6581214206
70-756-7662250242
80-864-8742285278
90-972-9822321314
100-1080-10902357350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%2.038.00.05.0%2.047.01.04.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%8.012.00.040.0%12.028.00.030.0%15.032.03.030.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%5.00.035.012.5%6.00.044.012.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%8.012.00.040.0%12.028.00.030.0%16.031.03.032.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ocular Therapeutix Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.307-0.248-19%0.625-149%0.089-445%0.082-475%0.031-1088%
Book Value Per Share--1.5701.958-20%0.800+96%1.002+57%0.757+107%0.526+198%
Current Ratio--10.22212.633-19%8.797+16%8.714+17%8.247+24%8.266+24%
Debt To Asset Ratio--0.3450.302+14%0.702-51%0.586-41%0.639-46%0.556-38%
Debt To Equity Ratio--0.5260.435+21%15.117-97%6.811-92%5.560-91%3.462-85%
Dividend Per Share----0%-0%-0%0.001-100%0.001-100%
Enterprise Value--1451370929.3701583002724.823-8%943138500.000+54%1056467908.274+37%1354853394.965+7%1283173597.482+13%
Eps---0.378-0.287-24%-0.181-52%-0.202-46%-0.170-55%-0.133-65%
Ev To Ebitda Ratio---5.677-9.457+67%-8.034+42%-8.592+51%-25.141+343%-24.954+340%
Ev To Sales Ratio--34.12127.280+25%15.873+115%18.575+84%40.405-16%327.118-90%
Free Cash Flow Per Share---0.275-0.221-20%-0.129-53%-0.152-45%-0.129-53%-0.107-61%
Free Cash Flow To Equity Per Share---0.250-0.199-21%0.642-139%0.113-322%0.098-355%0.046-640%
Gross Profit Margin--1.2211.192+2%5.914-79%2.881-58%2.053-41%1.618-25%
Intrinsic Value_10Y_max---7.573----------
Intrinsic Value_10Y_min---11.869----------
Intrinsic Value_1Y_max---0.478----------
Intrinsic Value_1Y_min---0.711----------
Intrinsic Value_3Y_max---1.650----------
Intrinsic Value_3Y_min---2.564----------
Intrinsic Value_5Y_max---3.081----------
Intrinsic Value_5Y_min---4.870----------
Market Cap1449630000.000+14%1241679929.3701315910724.823-6%870574500.000+43%944547158.274+31%1276808044.965-3%1227495422.482+1%
Net Profit Margin---6.023-3.471-42%-1.944-68%-2.408-60%-3.348-44%-15.231+153%
Operating Margin---6.304-3.395-46%-2.085-67%-2.358-63%-3.481-45%-14.752+134%
Operating Ratio--7.0174.653+51%2.539+176%3.271+115%3.595+95%15.648-55%
Pb Ratio5.797+19%4.6694.087+14%85.330-95%40.067-88%28.943-84%20.558-77%
Pe Ratio-6.017-24%-4.846-7.172+48%-65.987+1262%-26.844+454%-8.066+66%-15.294+216%
Price Per Share9.100+19%7.3307.853-7%5.465+34%5.793+27%7.934-8%7.665-4%
Price To Free Cash Flow Ratio-8.269-24%-6.661-9.181+38%-11.399+71%-10.257+54%-20.868+213%-23.369+251%
Price To Total Gains Ratio-29.645-24%-23.879-34.057+43%-1.508-94%-24.647+3%27.233-188%-151.379+534%
Quick Ratio--9.88512.269-19%8.516+16%8.433+17%7.991+24%9.262+7%
Return On Assets---0.158-0.106-33%-0.102-35%-0.122-23%-0.117-26%-0.153-3%
Return On Equity---0.241-0.153-36%-1.811+652%-1.066+342%-1.047+335%-0.756+214%
Total Gains Per Share---0.307-0.248-19%0.625-149%0.089-445%0.082-473%0.032-1064%
Usd Book Value--265930000.000327747500.000-19%127513500.000+109%164847166.667+61%123713400.000+115%85447950.000+211%
Usd Book Value Change Per Share---0.307-0.248-19%0.625-149%0.089-445%0.082-475%0.031-1088%
Usd Book Value Per Share--1.5701.958-20%0.800+96%1.002+57%0.757+107%0.526+198%
Usd Dividend Per Share----0%-0%-0%0.001-100%0.001-100%
Usd Enterprise Value--1451370929.3701583002724.823-8%943138500.000+54%1056467908.274+37%1354853394.965+7%1283173597.482+13%
Usd Eps---0.378-0.287-24%-0.181-52%-0.202-46%-0.170-55%-0.133-65%
Usd Free Cash Flow---46604000.000-37106750.000-20%-20481750.000-56%-24845666.667-47%-20953000.000-55%-17300700.000-63%
Usd Free Cash Flow Per Share---0.275-0.221-20%-0.129-53%-0.152-45%-0.129-53%-0.107-61%
Usd Free Cash Flow To Equity Per Share---0.250-0.199-21%0.642-139%0.113-322%0.098-355%0.046-640%
Usd Market Cap1449630000.000+14%1241679929.3701315910724.823-6%870574500.000+43%944547158.274+31%1276808044.965-3%1227495422.482+1%
Usd Price Per Share9.100+19%7.3307.853-7%5.465+34%5.793+27%7.934-8%7.665-4%
Usd Profit---64053000.000-48177750.000-25%-28816500.000-55%-33378833.333-48%-27507700.000-57%-21456875.000-67%
Usd Revenue--10634000.00014895500.000-29%14913250.000-29%14243000.000-25%12120900.000-12%6409450.000+66%
Usd Total Gains Per Share---0.307-0.248-19%0.625-149%0.089-445%0.082-473%0.032-1064%
 EOD+5 -3MRQTTM+5 -33YOY+16 -223Y+17 -215Y+13 -2710Y+20 -20

3.3 Fundamental Score

Let's check the fundamental score of Ocular Therapeutix Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.017
Price to Book Ratio (EOD)Between0-15.797
Net Profit Margin (MRQ)Greater than0-6.023
Operating Margin (MRQ)Greater than0-6.304
Quick Ratio (MRQ)Greater than19.885
Current Ratio (MRQ)Greater than110.222
Debt to Asset Ratio (MRQ)Less than10.345
Debt to Equity Ratio (MRQ)Less than10.526
Return on Equity (MRQ)Greater than0.15-0.241
Return on Assets (MRQ)Greater than0.05-0.158
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.065
Ma 20Greater thanMa 508.786
Ma 50Greater thanMa 1008.097
Ma 100Greater thanMa 2007.681
OpenGreater thanClose9.170
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-19 14:00:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Ocular Therapeutix Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -602.3% means that $-6.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -602.3%. The company is making a huge loss. -2
  • The TTM is -347.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-602.3%TTM-347.1%-255.2%
TTM-347.1%YOY-194.4%-152.7%
TTM-347.1%5Y-334.8%-12.3%
5Y-334.8%10Y-1,523.1%+1,188.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-602.3%-90.3%-512.0%
TTM-347.1%-141.5%-205.6%
YOY-194.4%-185.9%-8.5%
3Y-240.8%-248.0%+7.2%
5Y-334.8%-344.1%+9.3%
10Y-1,523.1%-489.2%-1,033.9%
4.3.1.2. Return on Assets

Shows how efficient Ocular Therapeutix Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -15.8% Return on Assets means that Ocular Therapeutix Inc generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ocular Therapeutix Inc:

  • The MRQ is -15.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.8%TTM-10.6%-5.2%
TTM-10.6%YOY-10.2%-0.4%
TTM-10.6%5Y-11.7%+1.1%
5Y-11.7%10Y-15.3%+3.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.8%-11.5%-4.3%
TTM-10.6%-11.6%+1.0%
YOY-10.2%-11.4%+1.2%
3Y-12.2%-11.9%-0.3%
5Y-11.7%-12.2%+0.5%
10Y-15.3%-13.9%-1.4%
4.3.1.3. Return on Equity

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -24.1% Return on Equity means Ocular Therapeutix Inc generated $-0.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ocular Therapeutix Inc:

  • The MRQ is -24.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.1%TTM-15.3%-8.7%
TTM-15.3%YOY-181.1%+165.8%
TTM-15.3%5Y-104.7%+89.4%
5Y-104.7%10Y-75.6%-29.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.1%-13.5%-10.6%
TTM-15.3%-15.0%-0.3%
YOY-181.1%-14.4%-166.7%
3Y-106.6%-17.0%-89.6%
5Y-104.7%-18.0%-86.7%
10Y-75.6%-20.4%-55.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ocular Therapeutix Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Ocular Therapeutix Inc is operating .

  • Measures how much profit Ocular Therapeutix Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • An Operating Margin of -630.4% means the company generated $-6.30  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -630.4%. The company is operating very inefficient. -2
  • The TTM is -339.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-630.4%TTM-339.5%-290.9%
TTM-339.5%YOY-208.5%-131.0%
TTM-339.5%5Y-348.1%+8.6%
5Y-348.1%10Y-1,475.2%+1,127.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-630.4%-229.5%-400.9%
TTM-339.5%-258.2%-81.3%
YOY-208.5%-204.2%-4.3%
3Y-235.8%-221.0%-14.8%
5Y-348.1%-344.1%-4.0%
10Y-1,475.2%-476.7%-998.5%
4.3.2.2. Operating Ratio

Measures how efficient Ocular Therapeutix Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.02 means that the operating costs are $7.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 7.017. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.653. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.017TTM4.653+2.364
TTM4.653YOY2.539+2.114
TTM4.6535Y3.595+1.058
5Y3.59510Y15.648-12.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0172.110+4.907
TTM4.6532.711+1.942
YOY2.5393.043-0.504
3Y3.2713.562-0.291
5Y3.5954.755-1.160
10Y15.6486.520+9.128
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ocular Therapeutix Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.22 means the company has $10.22 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 10.222. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.633. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.222TTM12.633-2.410
TTM12.633YOY8.797+3.835
TTM12.6335Y8.247+4.386
5Y8.24710Y8.266-0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.2223.662+6.560
TTM12.6333.745+8.888
YOY8.7974.104+4.693
3Y8.7144.649+4.065
5Y8.2475.734+2.513
10Y8.2666.143+2.123
4.4.3.2. Quick Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.89 means the company can pay off $9.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 9.885. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.269. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.885TTM12.269-2.384
TTM12.269YOY8.516+3.753
TTM12.2695Y7.991+4.278
5Y7.99110Y9.262-1.270
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8852.826+7.059
TTM12.2693.104+9.165
YOY8.5163.778+4.738
3Y8.4334.288+4.145
5Y7.9915.682+2.309
10Y9.2626.360+2.902
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ocular Therapeutix Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Ocular Therapeutix Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ocular Therapeutix Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that Ocular Therapeutix Inc assets are financed with 34.5% credit (debt) and the remaining percentage (100% - 34.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.345. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.302. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.345TTM0.302+0.043
TTM0.302YOY0.702-0.400
TTM0.3025Y0.639-0.337
5Y0.63910Y0.556+0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3450.324+0.021
TTM0.3020.349-0.047
YOY0.7020.329+0.373
3Y0.5860.339+0.247
5Y0.6390.349+0.290
10Y0.5560.384+0.172
4.5.4.2. Debt to Equity Ratio

Measures if Ocular Therapeutix Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 52.6% means that company has $0.53 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.526. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.435. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.526TTM0.435+0.091
TTM0.435YOY15.117-14.681
TTM0.4355Y5.560-5.125
5Y5.56010Y3.462+2.098
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5260.384+0.142
TTM0.4350.435+0.000
YOY15.1170.408+14.709
3Y6.8110.446+6.365
5Y5.5600.460+5.100
10Y3.4620.510+2.952
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ocular Therapeutix Inc generates.

  • Above 15 is considered overpriced but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A PE ratio of -4.85 means the investor is paying $-4.85 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -6.017. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.846. Based on the earnings, the company is expensive. -2
  • The TTM is -7.172. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.017MRQ-4.846-1.170
MRQ-4.846TTM-7.172+2.326
TTM-7.172YOY-65.987+58.815
TTM-7.1725Y-8.066+0.894
5Y-8.06610Y-15.294+7.228
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.017-2.150-3.867
MRQ-4.846-2.004-2.842
TTM-7.172-2.524-4.648
YOY-65.987-3.716-62.271
3Y-26.844-3.703-23.141
5Y-8.066-6.057-2.009
10Y-15.294-6.653-8.641
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -8.269. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.661. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.181. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.269MRQ-6.661-1.608
MRQ-6.661TTM-9.181+2.520
TTM-9.181YOY-11.399+2.218
TTM-9.1815Y-20.868+11.687
5Y-20.86810Y-23.369+2.501
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.269-3.030-5.239
MRQ-6.661-2.710-3.951
TTM-9.181-3.643-5.538
YOY-11.399-4.385-7.014
3Y-10.257-5.050-5.207
5Y-20.868-8.550-12.318
10Y-23.369-9.339-14.030
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Ocular Therapeutix Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.67 means the investor is paying $4.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ocular Therapeutix Inc:

  • The EOD is 5.797. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.669. Based on the equity, the company is fair priced.
  • The TTM is 4.087. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.797MRQ4.669+1.127
MRQ4.669TTM4.087+0.582
TTM4.087YOY85.330-81.242
TTM4.0875Y28.943-24.856
5Y28.94310Y20.558+8.386
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.7971.883+3.914
MRQ4.6691.855+2.814
TTM4.0872.119+1.968
YOY85.3302.469+82.861
3Y40.0672.504+37.563
5Y28.9433.657+25.286
10Y20.5584.297+16.261
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ocular Therapeutix Inc.

4.8.1. Institutions holding Ocular Therapeutix Inc

Institutions are holding 87.006% of the shares of Ocular Therapeutix Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Deep Track Capital, LP8.97333.392914294420145813811.3595
2025-03-31SUMMER ROAD LLC8.711998.22971387801885500.0616
2025-03-31VR Adviser, LLC8.01167.95991276246200
2025-03-31BlackRock Inc7.54080.0019120123971659101.4005
2025-03-31Vanguard Group Inc5.25080.00118364515-119398-1.4073
2025-03-31venBio Select Advisor LLC5.05960.9222806000000
2025-03-31TCG Crossover Management, LLC3.33915.3185531914800
2025-03-31Adage Capital Partners Gp LLC3.26430.07065200000160000044.4444
2025-03-31Citadel Advisors Llc3.02020.006748111083542987.9496
2025-03-31Geode Capital Management, LLC2.14840.00234224121861005.7504
2025-03-31State Street Corp2.12920.0013391850-98039-2.8092
2025-03-31Deltec Asset Management LLC1.70524.279527163731000003.8221
2025-03-31Octagon Capital Advisors LP1.52233.4395242500000
2025-03-31Logos Global Management LP1.44382.99692300000-1200000-34.2857
2025-03-31Morgan Stanley - Brokerage Accounts1.37380.0012218847836555320.0531
2025-03-31Point72 Asset Management, L.P.1.21930.03251942362-993562-33.8415
2025-03-31Opaleye Management Inc1.00132.6031595000-2747500-63.27
2025-03-31Paradigm Biocapital Advisors LP0.82490.4411131401813140180
2025-03-31Northern Trust Corp0.81040.00141290917-23954-1.8218
2025-03-31Longwood Capital Partners LLC0.765710.368412197241086539.7791
Total 68.1159140.07108508202+478767+0.4%

4.9.2. Funds holding Ocular Therapeutix Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv3.01790.00234807531972572.0648
2025-05-31iShares Russell 2000 ETF2.48740.0516396236800
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.26140.0164200946730080.1499
2025-03-31Fidelity Small Cap Index0.99220.04791580628368862.3894
2025-05-31iShares Russell 2000 Growth ETF0.8630.0997137470300
2025-04-30Fidelity Growth Compy Commingled Pl S0.82840.013813197011107658522.3742
2025-04-30Fidelity Select Pharmaceuticals Port0.60280.6785960217517100116.696
2025-04-30Fidelity Growth Company Fund0.59990.0135955678801778520.9734
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.57310.017891296028000.3076
2025-03-31Artisan Non-U.S. Small-Mid Growth Comp0.50640.1612806654-79367-8.9577
2025-03-31Artisan International Small-Mid Investor0.50640.1664806654-79367-8.9577
2025-04-30Vanguard Russell 2000 ETF0.49620.0555790383478566.445
2025-05-31Franklin Biotechnology Discv A(acc)USD0.4770.486775990000
2025-04-30Fidelity Extended Market Index0.44980.0165716565109071.5456
2025-04-30Strategic Advisers Fidelity US TtlStk0.42010.00386691506405002235.6021
2025-05-31Schwab US Small-Cap ETF™0.38150.0294607683-1628-0.2672
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.34020.0502541993-3400-0.6234
2025-04-30UTM IM GBP AXA Framlington Biotech0.33741.063953750200
2025-04-30Franklin Biotechnology Discovery A0.25740.480541010000
2025-03-31Peregrine Capital Mgt Sm-Cap Growth0.24750.56623943373943370
Total 15.6464.021824924174+3496325+14.0%

5.3. Insider Transactions

Insiders are holding 3.561% of the shares of Ocular Therapeutix Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-23Jeffrey S HeierSELL30247.18
2025-05-23Peter KaiserSELL29747.17
2025-05-23Pravin DugelSELL212197.18
2025-05-23Sanjay NayakSELL18627.17
2025-05-08Richard L Md LindstromBUY100006.96
2025-02-24Pravin DugelSELL214756.87
2025-02-04Donald NotmanSELL111197.81
2025-01-31Donald NotmanSELL63017.84
2024-11-25Jeffrey S HeierSELL29489.01
2024-08-23Sanjay NayakSELL18329.02
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets405,920
Total Liabilities139,990
Total Stockholder Equity265,930
 As reported
Total Liabilities 139,990
Total Stockholder Equity+ 265,930
Total Assets = 405,920

Assets

Total Assets405,920
Total Current Assets387,694
Long-term Assets18,226
Total Current Assets
Cash And Cash Equivalents 349,681
Net Receivables 25,221
Inventory 3,269
Other Current Assets 9,523
Total Current Assets  (as reported)387,694
Total Current Assets  (calculated)387,694
+/-0
Long-term Assets
Property Plant Equipment 16,612
Long-term Assets Other 1,614
Long-term Assets  (as reported)18,226
Long-term Assets  (calculated)18,226
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities37,926
Long-term Liabilities102,064
Total Stockholder Equity265,930
Total Current Liabilities
Short-term Debt 2,156
Accounts payable 4,626
Other Current Liabilities 31,080
Total Current Liabilities  (as reported)37,926
Total Current Liabilities  (calculated)37,862
+/- 64
Long-term Liabilities
Long term Debt 69,202
Capital Lease Obligations 7,022
Long-term Liabilities Other 144
Long-term Liabilities  (as reported)102,064
Long-term Liabilities  (calculated)76,368
+/- 25,696
Total Stockholder Equity
Common Stock16
Retained Earnings -955,137
Other Stockholders Equity 1,221,051
Total Stockholder Equity (as reported)265,930
Total Stockholder Equity (calculated)265,930
+/-0
Other
Capital Stock16
Cash and Short Term Investments 349,681
Common Stock Shares Outstanding 169,397
Current Deferred Revenue64
Liabilities and Stockholders Equity 405,920
Net Debt -273,457
Net Invested Capital 335,132
Net Working Capital 349,768
Property Plant and Equipment Gross 16,612
Short Long Term Debt Total 76,224



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
25,285
0
0
0
19,146
15,080
23,974
83,878
78,193
71,497
129,470
119,319
110,306
100,432
89,901
82,347
74,939
90,697
79,675
64,399
55,431
76,685
70,459
70,270
73,043
101,490
89,742
88,710
78,740
72,857
107,260
98,219
261,863
243,040
230,707
217,739
204,887
187,622
173,071
158,579
149,289
128,573
122,558
162,384
252,060
538,947
517,091
490,369
457,935
405,920
405,920457,935490,369517,091538,947252,060162,384122,558128,573149,289158,579173,071187,622204,887217,739230,707243,040261,86398,219107,26072,85778,74088,71089,742101,49073,04370,27070,45976,68555,43164,39979,67590,69774,93982,34789,901100,432110,306119,319129,47071,49778,19383,87823,97415,08019,14600025,285
   > Total Current Assets 
0
23,854
0
0
18,014
13,811
22,594
82,274
76,183
69,470
126,639
115,898
106,983
97,097
84,974
76,824
69,898
83,276
68,328
52,453
43,339
64,476
58,472
58,274
56,193
79,172
65,436
69,636
60,170
55,153
90,293
81,903
246,160
228,132
216,523
203,932
191,300
174,652
160,322
145,615
129,627
107,162
100,712
141,258
232,235
519,824
498,585
473,011
440,987
387,694
387,694440,987473,011498,585519,824232,235141,258100,712107,162129,627145,615160,322174,652191,300203,932216,523228,132246,16081,90390,29355,15360,17069,63665,43679,17256,19358,27458,47264,47643,33952,45368,32883,27669,89876,82484,97497,097106,983115,898126,63969,47076,18382,27422,59413,81118,0140023,8540
       Cash And Cash Equivalents 
23,854
-23,854
0
0
17,505
12,750
19,944
80,892
37,393
12,523
78,686
41,198
30,784
46,212
48,170
52,234
32,936
54,682
63,049
51,165
41,538
62,911
56,834
56,861
54,062
76,251
61,765
65,414
54,437
48,152
84,294
70,642
228,057
209,378
191,860
179,281
164,164
145,417
134,539
120,950
102,300
79,026
66,606
110,550
195,957
483,038
459,690
427,220
392,102
349,681
349,681392,102427,220459,690483,038195,957110,55066,60679,026102,300120,950134,539145,417164,164179,281191,860209,378228,05770,64284,29448,15254,43765,41461,76576,25154,06256,86156,83462,91141,53851,16563,04954,68232,93652,23448,17046,21230,78441,19878,68612,52337,39380,89219,94412,75017,50500-23,85423,854
       Short-term Investments 
60
47,708
0
0
60
60
60
60
37,435
54,900
45,036
72,445
74,280
49,244
35,717
23,513
35,209
25,697
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000003,00025,69735,20923,51335,71749,24474,28072,44545,03654,90037,435606060600047,70860
       Net Receivables 
0
0
0
0
19
306
61
54
329
352
164
189
193
227
223
243
250
244
211
278
226
170
285
240
201
276
615
1,114
2,548
3,429
2,874
7,779
12,252
13,631
18,734
19,552
21,135
23,207
20,482
19,802
21,325
21,124
27,309
23,589
26,179
26,546
30,232
30,235
32,388
25,221
25,22132,38830,23530,23226,54626,17923,58927,30921,12421,32519,80220,48223,20721,13519,55218,73413,63112,2527,7792,8743,4292,5481,1146152762012402851702262782112442502432232271931891643523295461306190000
       Inventory 
0
0
0
0
0
87
109
117
133
158
145
147
134
127
149
126
113
96
90
127
122
139
131
102
217
265
762
895
954
1,107
1,067
1,154
1,201
1,123
1,112
1,222
1,250
1,358
1,500
1,545
1,974
2,266
2,204
2,257
2,305
2,574
2,547
2,405
3,040
3,269
3,2693,0402,4052,5472,5742,3052,2572,2042,2661,9741,5451,5001,3581,2501,2221,1121,1231,2011,1541,0671,10795489576226521710213113912212790961131261491271341471451581331171098700000
   > Long-term Assets 
0
-23,854
0
0
1,132
1,269
1,380
1,604
2,010
2,027
2,831
3,421
3,323
3,335
4,927
5,523
5,041
7,421
11,347
11,946
12,092
12,209
11,987
11,996
16,850
22,318
24,306
19,074
18,570
17,704
16,967
16,316
15,703
14,908
14,184
13,807
13,587
12,970
12,749
12,964
19,662
21,411
21,846
21,126
19,825
19,123
18,506
17,358
16,948
18,226
18,22616,94817,35818,50619,12319,82521,12621,84621,41119,66212,96412,74912,97013,58713,80714,18414,90815,70316,31616,96717,70418,57019,07424,30622,31816,85011,99611,98712,20912,09211,94611,3477,4215,0415,5234,9273,3353,3233,4212,8312,0272,0101,6041,3801,2691,13200-23,8540
       Property Plant Equipment 
785
0
0
0
904
1,041
1,152
1,376
1,782
1,799
2,603
3,193
3,095
3,107
3,199
3,795
3,313
5,693
9,619
10,218
10,478
10,595
10,373
10,382
10,236
15,704
17,542
17,310
16,806
15,940
15,203
14,552
13,939
13,144
12,420
12,043
11,823
11,206
10,985
11,200
17,898
19,647
20,082
19,362
18,211
17,509
16,892
15,744
15,334
16,612
16,61215,33415,74416,89217,50918,21119,36220,08219,64717,89811,20010,98511,20611,82312,04312,42013,14413,93914,55215,20315,94016,80617,31017,54215,70410,23610,38210,37310,59510,47810,2189,6195,6933,3133,7953,1993,1073,0953,1932,6031,7991,7821,3761,1521,041904000785
       Long-term Assets Other 
0
-23,854
0
0
228
228
228
228
228
228
228
228
228
228
1,728
1,728
1,728
1,728
1,728
1,728
1,614
1,614
1,614
1,614
6,614
6,614
6,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
0
1,614
1,614
1,614
1,614
1,614
1,6141,6141,6141,6141,61401,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7646,7646,6146,6141,6141,6141,6141,6141,7281,7281,7281,7281,7281,72822822822822822822822822822822800-23,8540
> Total Liabilities 
6,073
0
0
0
78,618
3,933
93,409
18,276
19,497
19,424
20,358
20,511
20,718
20,262
19,453
20,053
22,931
26,792
31,650
28,477
29,284
27,501
24,730
24,753
37,168
75,842
81,484
77,409
82,370
83,516
101,916
102,345
185,768
159,632
150,460
130,399
116,888
107,827
107,268
112,350
113,910
118,862
119,471
154,531
160,929
130,964
139,396
138,348
142,591
139,990
139,990142,591138,348139,396130,964160,929154,531119,471118,862113,910112,350107,268107,827116,888130,399150,460159,632185,768102,345101,91683,51682,37077,40981,48475,84237,16824,75324,73027,50129,28428,47731,65026,79222,93120,05319,45320,26220,71820,51120,35819,42419,49718,27693,4093,93378,6180006,073
   > Total Current Liabilities 
3,475
0
0
0
3,342
2,069
4,489
3,379
5,874
7,227
9,591
11,181
5,378
6,003
6,419
8,243
8,300
8,656
13,130
10,945
13,426
13,151
11,899
13,406
9,159
8,614
10,127
11,005
12,029
11,112
13,803
22,906
26,664
27,437
21,550
25,158
26,337
23,960
26,113
29,269
31,395
29,715
32,357
35,066
34,896
24,298
29,972
36,359
41,354
37,926
37,92641,35436,35929,97224,29834,89635,06632,35729,71531,39529,26926,11323,96026,33725,15821,55027,43726,66422,90613,80311,11212,02911,00510,1278,6149,15913,40611,89913,15113,42610,94513,1308,6568,3008,2436,4196,0035,37811,1819,5917,2275,8743,3794,4892,0693,3420003,475
       Short-term Debt 
0
0
0
0
1,806
152
1,085
0
1,354
2,860
4,370
5,883
15,272
1,161
2,466
3,772
1,549
897
2,444
3,993
5,545
6,071
6,082
6,094
0
1,350
2,048
2,146
1,126
4,436
6,622
8,800
9,648
11,132
2,974
3,108
1,624
3,392
3,542
3,488
1,599
3,636
5,509
3,756
3,172
1,542
3,312
3,434
1,933
2,156
2,1561,9333,4343,3121,5423,1723,7565,5093,6361,5993,4883,5423,3921,6243,1082,97411,1329,6488,8006,6224,4361,1262,1462,0481,35006,0946,0826,0715,5453,9932,4448971,5493,7722,4661,16115,2725,8834,3702,8601,35401,0851521,8060000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
1,354
0
0
0
15,272
0
2,466
3,772
1,549
897
17,818
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
8,290
0
0
0
0
0
0
0
0
2,083
0
0
0
0
0
0
0
00000002,083000000008,2908,2906,2064,1462,07400067506,0946,0826,0715,5453,99317,8188971,5493,7722,466015,2720001,35400000000
       Accounts payable 
583
0
0
0
545
996
1,525
649
1,316
2,195
2,812
1,624
1,957
2,063
1,611
1,680
2,116
3,754
6,307
2,599
3,571
3,477
2,137
2,777
2,965
3,902
4,044
3,461
3,268
2,839
2,650
3,238
2,709
4,152
3,881
4,246
4,592
3,420
3,703
5,308
5,123
5,441
3,572
3,984
4,389
6,453
3,689
4,001
4,176
4,626
4,6264,1764,0013,6896,4534,3893,9843,5725,4415,1235,3083,7033,4204,5924,2463,8814,1522,7093,2382,6502,8393,2683,4614,0443,9022,9652,7772,1373,4773,5712,5996,3073,7542,1161,6801,6112,0631,9571,6242,8122,1951,3166491,525996545000583
       Other Current Liabilities 
1,086
0
0
0
741
671
1,629
2,480
3,016
1,922
2,284
3,591
3,379
2,779
2,342
2,791
4,635
4,005
4,379
4,353
4,310
3,603
3,680
4,535
6,194
3,362
4,035
5,398
7,635
3,837
4,531
10,868
14,307
12,153
14,695
17,804
20,121
15,940
17,679
19,870
24,097
20,175
22,885
27,009
27,080
16,040
22,702
27,017
37,050
31,080
31,08037,05027,01722,70216,04027,08027,00922,88520,17524,09719,87017,67915,94020,12117,80414,69512,15314,30710,8684,5313,8377,6355,3984,0353,3626,1944,5353,6803,6034,3104,3534,3794,0054,6352,7912,3422,7793,3793,5912,2841,9223,0162,4801,6296717410001,086
   > Long-term Liabilities 
0
0
0
0
75,276
1,864
88,920
14,897
13,623
12,197
10,767
9,330
15,340
14,259
13,034
11,810
14,631
18,136
18,520
17,532
15,858
14,350
12,831
11,347
28,009
67,228
71,357
66,404
70,341
72,404
88,113
79,439
159,104
132,195
128,910
105,241
90,551
83,867
81,155
83,081
82,515
89,147
87,114
119,465
126,033
106,666
109,424
101,989
101,237
102,064
102,064101,237101,989109,424106,666126,033119,46587,11489,14782,51583,08181,15583,86790,551105,241128,910132,195159,10479,43988,11372,40470,34166,40471,35767,22828,00911,34712,83114,35015,85817,53218,52018,13614,63111,81013,03414,25915,3409,33010,76712,19713,62314,89788,9201,86475,2760000
       Long term Debt Total 
0
0
0
0
0
0
13,594
14,776
13,511
12,094
10,673
9,249
15,272
14,204
12,992
11,778
14,094
16,821
15,374
13,924
12,471
11,014
9,548
8,073
24,788
47,857
48,796
48,098
49,312
48,286
47,322
42,766
41,243
39,729
50,239
50,822
51,435
52,058
52,695
53,344
54,006
54,679
53,284
0
0
0
0
0
0
0
000000053,28454,67954,00653,34452,69552,05851,43550,82250,23939,72941,24342,76647,32248,28649,31248,09848,79647,85724,7888,0739,54811,01412,47113,92415,37416,82114,09411,77812,99214,20415,2729,24910,67312,09413,51114,77613,594000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-1,806
-152
-1,085
0
-1,354
-2,860
-4,370
-5,883
-15,272
-1,161
-2,466
-3,772
-1,549
-897
-2,444
-3,993
-5,545
-6,071
-6,082
-6,094
0
7,234
8,469
8,133
8,905
5,335
2,872
406
-742
-2,542
5,283
4,801
5,924
3,776
3,228
2,866
8,678
6,296
3,893
5,373
5,292
6,407
4,444
3,875
5,345
4,866
4,8665,3453,8754,4446,4075,2925,3733,8936,2968,6782,8663,2283,7765,9244,8015,283-2,542-7424062,8725,3358,9058,1338,4697,2340-6,094-6,082-6,071-5,545-3,993-2,444-897-1,549-3,772-2,466-1,161-15,272-5,883-4,370-2,860-1,3540-1,085-152-1,8060000
       Warrants
0
0
0
0
0
0
74,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000074,355000000
       Long-term Liabilities Other 
0
0
0
0
0
0
852
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,909
9,493
9,206
8,905
8,590
8,256
7,909
19,548
19,169
18,770
18,355
18,924
18,575
17,999
18,143
22,158
21,554
104
106
108
111
114
117
141
144
14414111711411110810610421,55422,15818,14317,99918,57518,92418,35518,77019,16919,5487,9098,2568,5908,9059,2069,4937,909000000000000000000852000000
       Deferred Long Term Liability 
0
0
0
0
0
0
119
121
112
103
94
81
68
55
42
32
537
1,315
3,146
3,608
3,387
3,336
3,283
3,274
3,221
11,462
13,068
9,100
12,124
15,528
32,535
28,764
98,313
73,297
59,901
36,064
20,192
13,234
10,461
11,594
6,351
12,914
11,783
0
0
0
0
0
0
0
000000011,78312,9146,35111,59410,46113,23420,19236,06459,90173,29798,31328,76432,53515,52812,1249,10013,06811,4623,2213,2743,2833,3363,3873,6083,1461,315537324255688194103112121119000000
> Total Stockholder Equity
19,212
19,480
0
0
-59,472
11,147
-69,435
65,602
58,696
52,073
109,112
98,808
89,588
80,170
70,448
62,294
52,008
63,905
48,025
35,922
26,147
49,184
45,729
45,517
35,875
25,648
8,258
11,301
-3,630
-10,659
5,344
-4,126
76,095
83,408
80,247
87,340
87,999
79,795
65,803
46,229
35,379
9,711
3,087
7,853
91,131
407,983
377,695
352,021
315,344
265,930
265,930315,344352,021377,695407,98391,1317,8533,0879,71135,37946,22965,80379,79587,99987,34080,24783,40876,095-4,1265,344-10,659-3,63011,3018,25825,64835,87545,51745,72949,18426,14735,92248,02563,90552,00862,29470,44880,17089,58898,808109,11252,07358,69665,602-69,43511,147-59,4720019,48019,212
   Common Stock
0
0
0
0
-74,344
2
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
5
6
6
8
8
8
8
8
8
8
8
8
8
8
8
12
15
16
16
16
16
161616161512888888888888665554444443333322222222202-74,3440000
   Retained Earnings Total Equity0000000-667,842-647,160-616,842-601,300-577,112-558,346-545,804-541,954-544,611-536,130-539,251-453,639-441,695-405,127-383,615-357,598-338,820-314,367-297,243-279,844-264,834-251,030-237,265-224,163-208,596-189,902-173,879-161,057-151,461-140,016-129,176-118,539-107,015-97,006-89,428-81,474-74,180000000
   Accumulated Other Comprehensive Income 
0
-46,611
0
0
-1,675
-1,768
0
-83,878
-2,221
-2,221
-8
-16
-68
-2,939
10
5
-5
-9
0
-4,836
-5,341
0
0
0
-7,627
-7,627
0
0
-10,019
-10,019
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000-10,019-10,01900-7,627-7,627000-5,341-4,8360-9-5510-2,939-68-16-8-2,221-2,221-83,8780-1,768-1,67500-46,6110
   Capital Surplus 
0
0
0
0
0
0
4,745
147,074
148,122
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
260,082
263,409
300,210
310,559
325,357
333,114
340,011
347,074
368,894
379,980
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521
652,213
656,863
670,921
0
0
0
0
0
0
0
0000000670,921656,863652,213647,521642,907638,133633,795629,286624,850619,530615,338449,507447,033394,463379,980368,894347,074340,011333,114325,357310,559300,210263,409260,082256,618253,813225,889223,344221,897220,184218,830217,361216,133149,077148,122147,0744,745000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
77,581
78,933
-69,610
147,074
148,122
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
260,082
263,409
300,210
310,559
325,357
333,114
340,011
347,074
368,894
379,980
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521
652,213
656,863
670,921
676,203
788,697
1,170,394
1,183,882
1,194,701
1,206,412
1,221,051
1,221,0511,206,4121,194,7011,183,8821,170,394788,697676,203670,921656,863652,213647,521642,907638,133633,795629,286624,850619,530615,338449,507447,033394,463379,980368,894347,074340,011333,114325,357310,559300,210263,409260,082256,618253,813225,889223,344221,897220,184218,830217,361216,133149,077148,122147,074-69,61078,93377,5810000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue63,723
Cost of Revenue-5,626
Gross Profit58,09758,097
 
Operating Income (+$)
Gross Profit58,097
Operating Expense-229,878
Operating Income-171,781-171,781
 
Operating Expense (+$)
Research Development127,635
Selling General Administrative60,653
Selling And Marketing Expenses41,590
Operating Expense229,878229,878
 
Net Interest Income (+$)
Interest Income20,282
Interest Expense-13,577
Other Finance Cost-0
Net Interest Income6,705
 
Pretax Income (+$)
Operating Income-171,781
Net Interest Income6,705
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-193,506-150,056
EBIT - interestExpense = -193,506
-193,506
-179,929
Interest Expense13,577
Earnings Before Interest and Taxes (EBIT)-179,929-179,929
Earnings Before Interest and Taxes (EBITDA)-176,143
 
After tax Income (+$)
Income Before Tax-193,506
Tax Provision-0
Net Income From Continuing Ops-193,506-193,506
Net Income-193,506
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses235,504
Total Other Income/Expenses Net-21,725-6,705
 

Technical Analysis of Ocular Therapeutix Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ocular Therapeutix Inc. The general trend of Ocular Therapeutix Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ocular Therapeutix Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ocular Therapeutix Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ocular Therapeutix Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.25 < 11.25 < 11.78.

The bearish price targets are: 8.03 > 8.03 > 6.86.

Know someone who trades $OCUL? Share this with them.👇

Ocular Therapeutix Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ocular Therapeutix Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ocular Therapeutix Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ocular Therapeutix Inc. The current macd is 0.33875754.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ocular Therapeutix Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ocular Therapeutix Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ocular Therapeutix Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ocular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) ChartOcular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ocular Therapeutix Inc. The current adx is 29.56.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ocular Therapeutix Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Ocular Therapeutix Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ocular Therapeutix Inc. The current sar is 8.19348352.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ocular Therapeutix Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ocular Therapeutix Inc. The current rsi is 59.06. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Ocular Therapeutix Inc Daily Relative Strength Index (RSI) ChartOcular Therapeutix Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ocular Therapeutix Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ocular Therapeutix Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ocular Therapeutix Inc Daily Stochastic Oscillator ChartOcular Therapeutix Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ocular Therapeutix Inc. The current cci is 81.54.

Ocular Therapeutix Inc Daily Commodity Channel Index (CCI) ChartOcular Therapeutix Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ocular Therapeutix Inc. The current cmo is 17.53.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ocular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) ChartOcular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ocular Therapeutix Inc. The current willr is -45.68527919.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ocular Therapeutix Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ocular Therapeutix Inc Daily Williams %R ChartOcular Therapeutix Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ocular Therapeutix Inc.

Ocular Therapeutix Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ocular Therapeutix Inc. The current atr is 0.54096594.

Ocular Therapeutix Inc Daily Average True Range (ATR) ChartOcular Therapeutix Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ocular Therapeutix Inc. The current obv is 21,722,197.

Ocular Therapeutix Inc Daily On-Balance Volume (OBV) ChartOcular Therapeutix Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ocular Therapeutix Inc. The current mfi is 26.40.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ocular Therapeutix Inc Daily Money Flow Index (MFI) ChartOcular Therapeutix Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ocular Therapeutix Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Ocular Therapeutix Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.065
Ma 20Greater thanMa 508.786
Ma 50Greater thanMa 1008.097
Ma 100Greater thanMa 2007.681
OpenGreater thanClose9.170
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ocular Therapeutix Inc with someone you think should read this too:
  • Are you bullish or bearish on Ocular Therapeutix Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ocular Therapeutix Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ocular Therapeutix Inc.

Receive notifications about Ocular Therapeutix Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.